SCHEMBL9936674

SCHEMBL9936674

O=C(O)c1nccc2[nH]ccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
KDM4E B2RXH2 5/20 0.42
ASPH Q12797 1/20 0.42
KDM8 Q8N371 1/20 0.42
EGLN1 Q9GZT9 1/20 0.41
TRPA1 O75762 2/20 0.41
ALDH1A1 P00352 3/20 0.40
MAPT P10636 2/20 0.40
CYP3A4 P08684 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
BLM P54132 1/20 0.40
AGER Q15109 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HPGD P15428 1/20 0.37
ENPP2 Q13822 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MCL1 Q07820 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15059574 0.84 PDE3B (0.61) PDE3BPDE3AEGLN1TRPA1HCRTR2
SCHEMBL1655505 0.80 KDM4E (0.46) PDE3BPDE3AKDM4EEGLN1TRPA1
SCHEMBL27977181 0.80 PDE3B (0.42) PDE3BPDE3AEGLN1TRPA1HCRTR2
SCHEMBL24774355 0.75 KMT2A (0.45) KDM4EEGLN1ALDH1A1MAPTTSHR
SCHEMBL5259159 0.74 NUDT1 (0.39) TRPA1IKBKBCHUKNUDT1DRD1
SCHEMBL30110684 0.74 MAP2K4 (0.50) PDE3BPDE3AKDM4EALDH1A1HPGD
SCHEMBL24126726 0.74 MAP2K4 (0.50) PDE3BPDE3AKDM4EALDH1A1HPGD
SCHEMBL31178673 0.73 METTL3 (0.45) PDE3BPDE3AKDM4EASPHKDM8
SCHEMBL17159727 0.73 METTL3 (0.45) PDE3BPDE3AKDM4EASPHKDM8
SCHEMBL1154939 0.72 TRPA1 (0.45) TRPA1ALOX15NPSR1IKBKBCHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103992319-A Pyridine carboxylic acid compounds and preparation method thereof SPHINX SCIENT LAB CORP 2014-08-20 CN claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 CN disclosed
WO-2024153244-A1 NITROGEN-CONTAINING COMPOUND 南京再明医药有限公司 2024-07-25 WO disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
CN-108137542-B Pyridone dicarboxamides as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2023-10-27 CN disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 US disclosed
EP-3157938-B1 HETERO FUNCTIONAL BINDING SYSTEMS ANTEO TECH PTY LTD (AU) 2022-03-16 EP disclosed
WO-2017037116-A1 PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-03-09 WO disclosed
EP-2694509-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN-RELATED KINASES PFIZER LTD (GB) 2016-05-18 EP disclosed
CN-103992319-B A kind of preparation method of pyridine carboxylic acid compounds Tianjin Sphinx Medicine R&D Co., Ltd. (CN) 2015-09-16 CN disclosed
CN-103992319-B A kind of preparation method of pyridine carboxylic acid compounds Tianjin Sphinx Medicine R&D Co., Ltd. (CN) 2015-09-16 CN disclosed
EP-2766344-A1 EP1 RECEPTOR LIGANDS Laboratorios Del. Dr. Esteve, S.A. (ES) 2014-08-20 EP disclosed
CN-103992319-A Pyridine carboxylic acid compounds and preparation method thereof SPHINX SCIENT LAB CORP 2014-08-20 CN disclosed
CN-103992319-A Pyridine carboxylic acid compounds and preparation method thereof SPHINX SCIENT LAB CORP 2014-08-20 CN disclosed
EP-2651919-A1 DIMERIC IAP INHIBITORS Novartis AG (CH) 2013-10-23 EP disclosed
WO-2013037960-A1 EP1 RECEPTOR LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2013-03-21 WO disclosed
WO-2012080271-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP PDE3B 592/4885PDE3A 599/4885KDM4E 2437/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH PDE3B 675/4885PDE3A 703/4885KDM4E 3565/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP PDE3B 592/4885PDE3A 599/4885KDM4E 2437/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP PDE3B 592/4885PDE3A 599/4885KDM4E 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.